See more : Nippon Concept Corporation (9386.T) Income Statement Analysis – Financial Results
Complete financial analysis of Nabriva Therapeutics plc (NBRV) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Nabriva Therapeutics plc, a leading company in the Biotechnology industry within the Healthcare sector.
- L.K. Technology Holdings Limited (0558.HK) Income Statement Analysis – Financial Results
- Crown LNG Holdings Limited Warrants (CGBSW) Income Statement Analysis – Financial Results
- MercadoLibre, Inc. (MLB1.DE) Income Statement Analysis – Financial Results
- China Life Insurance Company Limited (2628.HK) Income Statement Analysis – Financial Results
- Nobland (145170.KQ) Income Statement Analysis – Financial Results
Nabriva Therapeutics plc (NBRV)
About Nabriva Therapeutics plc
Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, hospital-acquired bacterial pneumonia, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 35.67M | 27.22M | 2.86M | 7.75M | 6.50M | 0.00 | 0.00 | 84.00K | 0.00 | 0.00 |
| Cost of Revenue | 28.58M | 13.15M | 766.00K | 70.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 7.09M | 14.07M | 2.10M | 7.68M | 6.50M | 0.00 | 0.00 | 84.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 19.87% | 51.69% | 73.25% | 99.10% | 100.00% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% |
| Research & Development | 14.26M | 12.63M | 15.10M | 26.42M | 82.29M | 49.62M | 47.99M | 22.73M | 8.59M | 10.11M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 41.74M | 29.47M | 13.44M | 7.82M | 3.46M | 3.91M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 45.26M | 51.65M | 55.29M | 62.49M | 41.74M | 29.47M | 13.44M | 7.82M | 3.46M | 3.91M |
| Other Expenses | -1.27M | -1.68M | -2.16M | -1.73M | -272.00K | 492.00K | 55.00K | 2.86M | 77.82K | 34.30M |
| Operating Expenses | 58.26M | 62.60M | 68.22M | 87.17M | 120.88M | 73.77M | 55.05M | 26.84M | 9.89M | 6.74M |
| Cost & Expenses | 86.84M | 75.74M | 68.99M | 87.24M | 120.88M | 73.77M | 55.05M | 26.84M | 9.89M | 6.74M |
| Interest Income | 0.00 | 0.00 | 86.00K | 255.00K | 49.00K | 318.00K | 343.00K | 6.74M | 2.43K | 307.93K |
| Interest Expense | 698.00K | 0.00 | 1.74M | 3.64M | 133.00K | 43.00K | 75.00K | 14.59M | 6.98M | 5.55M |
| Depreciation & Amortization | -3.53M | 637.00K | 1.27M | 470.00K | 510.00K | 432.00K | 233.00K | 150.88K | 152.00K | 197.46K |
| EBITDA | -54.70M | -48.53M | -64.85M | -79.02M | -114.09M | -72.53M | -54.42M | -17.24M | -9.75M | 28.06M |
| EBITDA Ratio | -153.36% | -178.31% | -2,264.42% | -1,019.86% | -1,755.20% | 0.00% | 0.00% | -20,518.94% | 0.00% | 0.00% |
| Operating Income | -51.17M | -48.53M | -66.13M | -79.49M | -114.38M | -73.77M | -55.05M | -23.98M | -9.77M | 22.31M |
| Operating Income Ratio | -143.47% | -178.31% | -2,308.87% | -1,025.93% | -1,759.62% | 0.00% | 0.00% | -28,544.30% | 0.00% | 0.00% |
| Total Other Income/Expenses | -4.44M | -432.00K | -3.22M | -3.17M | -356.00K | 767.00K | -515.00K | 2.86M | -6.42M | -5.76M |
| Income Before Tax | -55.62M | -48.96M | -69.35M | -82.66M | -114.73M | -73.00M | -55.56M | -31.82M | -16.18M | 16.55M |
| Income Before Tax Ratio | -155.93% | -179.89% | -2,421.26% | -1,066.89% | -1,765.09% | 0.00% | 0.00% | -37,886.83% | 0.00% | 0.00% |
| Income Tax Expense | 1.57M | 490.00K | 139.00K | 101.00K | 49.00K | 1.36M | -672.00K | -438.41K | 87.55K | 1.07M |
| Net Income | -57.19M | -49.45M | -69.48M | -82.76M | -114.78M | -74.36M | -54.89M | -31.39M | -16.27M | 15.48M |
| Net Income Ratio | -160.33% | -181.69% | -2,426.12% | -1,068.20% | -1,765.85% | 0.00% | 0.00% | -37,364.91% | 0.00% | 0.00% |
| EPS | -21.32 | -28.52 | -135.23 | -278.86 | -564.91 | -623.15 | -638.90 | -741.38 | -149.52 | 142.25 |
| EPS Diluted | -21.32 | -28.52 | -135.23 | -278.86 | -564.91 | -623.15 | -638.90 | -741.38 | -149.52 | 130.92 |
| Weighted Avg Shares Out | 2.68M | 1.73M | 513.80K | 296.80K | 203.18K | 119.32K | 85.91K | 42.34K | 108.82K | 108.82K |
| Weighted Avg Shares Out (Dil) | 2.68M | 1.73M | 513.80K | 296.80K | 203.18K | 119.32K | 85.91K | 42.34K | 108.82K | 108.82K |
Down 25.5% in 4 Weeks, Here's Why You Should You Buy the Dip in Nabriva Therapeutics AG (NBRV)
Nabriva Therapeutics (NBRV) Sees Hammer Chart Pattern: Time to Buy?
Nabriva Therapeutics (NBRV): Q3 2021 Financial Results
Nabriva Therapeutics plc (NBRV) CEO Theodore Schroeder on Q3 2021 Results - Earnings Call Transcript
Nabriva Therapeutics to Present at the Jefferies London Healthcare Conference
Nabriva Therapeutics to Report Third Quarter 2021 Financial Results and Recent Corporate Highlights on November 9, 2021
Nabriva Therapeutics to Present Data at CHEST Annual Meeting 2021
Nabriva Publishes Data Demonstrating the Potent Anti-Inflammatory Properties of XENLETA® (lefamulin)
Nabriva Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Nabriva Therapeutics Appoints Dr. Christine Guico-Pabia, M.D., as Chief Medical Officer
Source: https://incomestatements.info
Category: Stock Reports